基于前列腺影像报告和数据系统2.1版的有临床意义前列腺癌诊断预测模型
本研究回顾性分析2019年4月至2023年12月在本机构接受前瞻性多参数磁共振成像(mpMRI)PI-RADS v2.1评分及活检的患者数据,构建并验证了纳入临床资料与PI-RADS v2.1评分的「MRI Added」模型和仅用临床资料的「Clinical Baseline」模型,并在内部和外部队列中与两个已发表的基于MRI的算法比较。结果显示「MRI Added」模型判别能力显著优于「Clinical Baseline」模型(内部AUC 0.88 vs 0.75,外部AUC 0.79 vs 0.68,P < 0.001),在25%风险阈值下较「全部活检」策略分别减少27%(内部队列)和10%(外部队列)的不必要活检,但与针对PI-RADS v2和v1开发的比较模型在预测能力和减少不必要活检方面无显著差异。
要点
- 「MRI Added」模型内部AUC 0.88、外部AUC 0.79,均显著优于「Clinical Baseline」模型(内部0.75、外部0.68,P < 0.001)。
- 25%风险阈值下,「MRI Added」模型较「全部活检」策略减少不必要活检:内部队列27%,外部队列10%。
- 与针对PI-RADS v2和v1开发的比较模型相比,本模型预测能力及减少不必要活检方面无显著差异。
核心结论
- 基于PI-RADS v2.1的mpMRI模型显著提高有临床意义前列腺癌(csPCa)的预测能力,在准确性和减少不必要活检方面优于传统临床模型。
- 该模型在不同患者人群中显示出应用前景,为前列腺癌的检测和管理提供了更新的整合方法。
研究设计与样本
- 回顾性分析2019年4月至2023年12月在本机构接受前瞻性mpMRI评估(PI-RADS v2.1评分)并接受活检的患者数据。
- 构建「Clinical Baseline」模型(人口学与实验室结果)和「MRI Added」模型(额外纳入PI-RADS v2.1评分与前列腺体积),并在内部和外部患者中验证。
- 共纳入内部和外部队列1319例患者。
- 用受试者工作特征曲线下面积(AUC)和决策曲线分析,将两个模型与两个已发表的基于MRI的csPCa算法进行比较。
主要发现
- 「MRI Added」模型判别能力显著优于「Clinical Baseline」模型:内部队列AUC 0.88 vs 0.75,外部队列AUC 0.79 vs 0.68(P < 0.001)。
- 「MRI Added」模型在多个临床阈值概率下显示更高的净获益。
- 在25%风险阈值下,与「全部活检」策略相比,「MRI Added」模型减少不必要活检(定义为未检出Gleason分级分组≥2 csPCa的活检):内部队列减少27%,外部队列减少10%。
- 本模型与针对PI-RADS v2和v1开发的比较模型在预测能力和减少不必要活检方面无显著差异。
关键数值与推荐
- 「MRI Added」模型内部AUC 0.88,外部AUC 0.79。
- 「Clinical Baseline」模型内部AUC 0.75,外部AUC 0.68。
- 两模型AUC比较P < 0.001。
- 25%风险阈值下,「MRI Added」模型较「全部活检」减少不必要活检:内部队列27%,外部队列10%。
- 不必要活检定义为未检出Gleason分级分组≥2 csPCa的活检。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To develop and validate a Prostate Imaging-Reporting and Data System (PI-RADS) version 2.1 (v2.1)-based predictive model for diagnosis of clinically significant prostate cancer (csPCa), integrating clinical and multiparametric magnetic resonance imaging (mpMRI) data, and compare its performance with existing models. PATIENTS AND METHODS: We retrospectively analysed data from patients who underwent prospective mpMRI assessment using the PI-RADS v2.1 scoring system and biopsy at our institution between April 2019 and December 2023. A 'Clinical Baseline' model using patient demographics and laboratory results and an 'MRI Added' model additionally incorporating PI-RADS v2.1 scores and prostate volumes were created and validated on internal and external patients. Both models were compared against two previously published MRI-based algorithms for csPCa using area under the receiver operating characteristic curve (AUC) and decision curve analysis. RESULTS: A total of 1319 patients across internal and external cohorts were included. Our 'MRI Added' model demonstrated significantly improved discriminative ability (AUCinternal 0.88, AUCexternal 0.79) compared to our 'Clinical Baseline' model (AUCinternal 0.75, AUCexternal 0.68) (P < 0.001). The 'MRI Added' model also showed higher net benefits across various clinical threshold probabilities and compared to a 'biopsy all' approach, it reduced unnecessary biopsies (defined as biopsies without Gleason Grade Group ≥2 csPCa) by 27% in the internal cohort and 10% in the external cohort at a risk threshold of 25%. However, there was no significant difference in predictive ability and reduction in unnecessary biopsies between our model and comparative ones developed for PI-RADS v2 and v1. CONCLUSION: Our PI-RADS v2.1-based mpMRI model significantly enhances csPCa prediction, outperforming the traditional clinical model in accuracy and reduction of unnecessary biopsies. It proves promising across diverse patient populations, establishing an updated, integrated approach for detection and management of prostate cancer.
引用
- Gelikman DG, Azar WS, Yilmaz EC, et al. A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis. BJU Int. 2024. PMID: 39654290. doi:10.1111/bju.16616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。